The latest approval for Lynparza in Europe is for its use as a monotherapy for adult patients with germline BRCA1/2-mutations (gBRCAm), and who have human epidermal growth factor
The post Lynparza secures European approval for type of advanced breast cancer appeared first on Pharmaceutical Business review.
Original Article: Lynparza secures European approval for type of advanced breast cancer